Physician profile
Ivelisse Cruz
NPI 1497324396
$932.72
in general payments reported to CMS, 2019-2025
18 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589 · 2022: $52.12 · 2023: $14.58 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.29 | 2025 | Ozempic, Wegovy |
| Ucb, INC. | $150.91 | 2021 | |
| Neurelis, INC. | $136.53 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $76.96 | 2021 | |
| Tris Pharma INC | $54.28 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.52 | 2021 | |
| Corium, LLC | $34.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.26 | 2022-2023 | Xarelto |
| Madrigal Pharmaceuticals | $25.00 | 2025 | Rezdiffra |
| Lilly USA, LLC | $24.42 | 2025 | Zepbound, Mounjaro |
| Aquestive Therapeutics, INC. | $22.30 | 2021 | |
| Eisai INC. | $18.23 | 2021 | |
| Zogenix INC. | $16.60 | 2021 | |
| Ns Pharma, INC. | $14.97 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.78 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $14.29 | 2025 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivelisse Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.